Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
SALT LAKE CITY, Dec. 28, 2016 -- Great Basin Scientific, Inc. (OTCQB:GBSND), a molecular diagnostics company, announced today that its stock is currently trading under a temporary symbol of GBSND on the OTCQB market. The symbol will revert to GBSN on January 24, 2017. The temporary symbol is standard procedure for OTC-listed companies to notify shareholders of a reverse split.
About Great Basin Scientific
Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses, and significantly limiting the spread of infectious disease. More information can be found on the company’s website at www.gbscience.com.
Forward-Looking Statements
This press release includes forward-looking statements regarding the Company’s continuing business efforts related to its products, including but not limited to, statements regarding the effective date of the reverse stock split and increase in authorized shares, the Company’s development plans and other similar statements. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: (i) our limited operating history and history of losses; (ii) our ability to develop and commercialize new products and the timing of commercialization; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2016. These forward-looking statements speak only as of the date hereof and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.
Investor Relations Contact: Betsy Hartman, Great Basin Scientific 385.215.3372 [email protected] Media Contact: Nirav Suchak, ICR 646.277.1257 [email protected]
